Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
Status:
Completed
Trial end date:
2020-09-19
Target enrollment:
Participant gender:
Summary
The purpose of the proposed study is to compare insulin Degludec [TRESIBA® (insulin degludec
injection)] with insulin Glargine U100 [Lantus® (insulin glargine injection)] to determine
the basal insulin of choice for adults with type 1 diabetes (T1D) who fly non-stop across
multiple time zones. With the introduction of Degludec as basal insulin for T1D and the
opportunity to vary time of injection between 8 and 40 hours, the use of Degludec as a basal
insulin may make it easier for both people living with T1D and diabetologists to plan
long-haul travel compared to the use of existing basal insulins when crossing multiple time
zones.The study hypothesis is that once daily Degludec as the basal insulin will provide
better glycemic control for people with type 1 diabetes on multiple daily injections who are
traveling non-stop across multiple time zones than once daily Glargine U100.